Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284875 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
A Phase 3 study of Obesity and Overweight, sponsored by Kailera.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
- 20
- Study locations
NCT07284875: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Kailera.
NCT07284875 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Kailera. The registered enrollment target is 1,800 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284875, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Kailera.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KAI-9531
Study Locations (20)
Texas
- Kailera Clinical Site - Amarillo
- Kailera Clinical Site - DeSoto
- Kailera Clinical Site - Tomball
Alabama
- Kailera Clinical Site - Anniston
- Kailera Clinical Site - Cullman
California
- Kailera Clinical Site - Escondido
- Kailera Clinical Site - Toluca Lake
Arizona
- Kailera Clinical Site - Sun City
Colorado
- Kailera Clinical Site - Aurora
Connecticut
- Kailera Clinical Site - Bridgeport
Florida
- Kailera Clinical Site - Jupiter
Georgia
- Kailera Clinical Site - Lilburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2028-03-27 |
| Phase | Phase 3 |
What NCT07284875 shows while recruiting
NCT07284875 is an interventional study that assigns participants to a tested intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (120% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07284875 names 20 study sites across 16 states, led by Texas, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT07284875 about?
NCT07284875 is a clinical study titled "Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes". The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
What is the current status of trial NCT07284875?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2025-12-18. Estimated completion is 2028-03-27.
What conditions does trial NCT07284875 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07284875?
The interventions under investigation include: Placebo (DRUG), KAI-9531 (DRUG).
Who is sponsoring clinical trial NCT07284875?
This trial is sponsored by Kailera, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284875 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284875's enrollment target sits among peer trials
1,800 49th of 1053 higher than 1,004 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI